GPCR Structure Therapeutics Inc - ADR

$GPCR $VKTX GPCR and Viking will likely be fine long term but there are a few things being missed as to why Viking has a higher enterprise value. 1) Viking is year ahead in development 2) VK2735 has near industry leading weight loss and is also a dual agonist 3) GIP mitigates side effects and improves the metabolic properties of GLP’s 4) Peptides are the future of medicine and the biggest selling drug in the world is a peptide…

$GPCR $VKTX $KLRA I know many of us watch the biotech obesity segment as a whole and it has gotten HAMMERED the past couple months across the board. KLRA's data wasn't great in July/Aug, so that explains their drop. GPCR announced successful SAD testing on the world's first oral amylin and stock has dropped ever since. VKTX had great SQ data, dilution, and crash. Anyway, seems like there is a concerted effort to bring these stocks down. Looking for someone more familiar with market dynamics to shed some light on the recent sector crash. I have two theories: 1. Institutional investors aren't concerned with any of these companies getting BP deals in the next 3-6 months and collectively are shorting them down to make $$$ and then planning to make money on the way back up. "Taking advantage of the ridiculously long Ph3 trials". 2. BP is somehow controlling the institutional investors and are trying to suppress the share price on these companies to prevent commercial scaling funding.

$GPCR the drop here is absolutely hilarious (in a bad way). Does everyone realize they hold 1.3B in cash and no debt. Yet this trades with a mkt cap of 1.9B. --so youre telling me all of Structure's assets together are worth only 600M. And dont ge tme started on Viking... what a nightmare.

$GPCR the institutions that bought into their most recent equity raise … aren’t they calling Ray saying WTF … take the money bro

$GPCR $VKTX GPCR vs. VKTX (Oct. 15, 2025–Oct. 15, 2026): GPCR: Market cap fell ~$1.77B→$1.58B (−11%), while cash rose ~$799M→$1.33B following equity financing. Debt remains negligible. Enterprise value collapsed ~$975M→$246M (−75%). VKTX: Market cap fell ~$3.97B→$3.44B (−13%). Cash increased to ~$1.05B following $575M financing, including $259M convertible debt. EV declined ~$3.25B→$2.7B (−17%). Takeaway: The biotech selloff, dilution concerns and increasingly competitive obesity market pressured both stocks. However, GPCR suffered dramatically greater EV compression despite advancing its oral obesity program to Ph3. Viking retains an approximately 11× EV premium over GPCR, reflecting stronger clinical validation but also substantially higher expectations.

$GPCR 16 analyst cover this company, 70-145 dollar targets. As recent as less tha. 30 days ago....3 price targets were reaffirmed after data on 9/8, 104, 110, and 111 dollar targets. The stock is under 28 dollars now, 1.3 billion cash, less than 2 billion market cap and several trials going on, 5 billion dollars is a price any company can buy this up while its cheap. It is undervalued is what im saying lol

$GPCR market too big for 3-4 players. Worse products comming later with massive investments behind from big pharma. This proce is just absurd and not linked to aleni value. Just a matter of time. Buying more

$GPCR almost at cash value now. And doesnt even include the values from all their trials. Nothing but silence too the last month, 43% down just in last 30 days. Still no sign of bottom though

$GPCR damn, wtf happened since I’ve brought you profits within days and then left. Everytime i leave, profits erode, vanquished, poof and more bagholders created. Well, I’m back. Starter again. Best be welcoming me with open arms Jabronis if you 👃 👃 👃 what the 📈 is 🧑‍🍳 . Ah, nevermind.

$GPCR in today's Lilly Quarterly Report, look at how many trials and extensions that Lilly is working on for Foundayo. Weight-Loss, Diabetes, Sleep Apnea, Pain Management, etc, etc. They know that Foundayo is the future and the first / biggest competitor to Foundayo will be Aleniglipron. Current share price is depressing, but this one is going to fly... In UK, Foundayo is priced around $150 a month with Tirz above $300 a month. When Lilly starts dropping the price in the US and Foundayo gets approved for diabetes, it will start to eat away at SQ market share, IMO. The only reason they haven't dropped the US price of Foundayo is the SQ market share they would be eating away at is their own Zepbound / Mounjaro, so they have no need to cut their own profit margins at the moment.

$GPCR Price: $N/A Volume: Average Catalyst: Investors await updated obesity/metabolic pipeline data from Structure Therapeutics' oral GLP-1 candidates. Resistance: $38 Support: $29 Bull case: A clean break above $38 on rising volume could signal renewed confidence ahead of next trial readouts. Bear case: Failure to hold $29 support may trigger further downside if sentiment on oral GLP-1 competition sours. What I'm watching: Watching for a volume spike near resistance to confirm breakout strength before any entry. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio:

$GPCR Approaching $20, this is where the SP would be if Aleniglipron failed, right? But it hasnt, and their Amylin drug passed SAD and is actively in MAD testing. So either we arent being told something, or this share price is just crazy!

$GPCR besides Elly’s oral product there is nothing out there in non-peptide that comes close to aleniglipron and even then this asset has better data thus far!

$GPCR one month down from 47 dollars to 27, 40-45% down. Last 8 days, all red, 36-27. Absolute slaughterfest going on here by the hedge funds. Remember many short and buy shares. Cant beleive management has allowed this rough month to continue by being so silent, yet hard not to be ullish long term here when its 27 with a great balance sheet and all the ongoing trials.

$GPCR time to stock up. Metsera executive hired for a reason. AbbVie will come calling soon!

$GPCR 1.5B market cap with 1.3B in cash. I think that shows what people think of their drug and their future. basically, its worthless.

$GPCR Opening orders for this security cannot be accepted at this time......Why is that? I haven't been following this one.

$GPCR Falling knife. Would I buy at this level? Sure. I’d even start a position at $30. But need to see this show strength first